SI2257307T1 - Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic - Google Patents
Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celicInfo
- Publication number
- SI2257307T1 SI2257307T1 SI200931870T SI200931870T SI2257307T1 SI 2257307 T1 SI2257307 T1 SI 2257307T1 SI 200931870 T SI200931870 T SI 200931870T SI 200931870 T SI200931870 T SI 200931870T SI 2257307 T1 SI2257307 T1 SI 2257307T1
- Authority
- SI
- Slovenia
- Prior art keywords
- recombinant
- glycosylated proteins
- procaryotic cells
- bioconjugates
- bioconjugates made
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6416308P | 2008-02-20 | 2008-02-20 | |
US7154508P | 2008-05-05 | 2008-05-05 | |
US12948008P | 2008-06-30 | 2008-06-30 | |
US12985208P | 2008-07-24 | 2008-07-24 | |
US13668708P | 2008-09-25 | 2008-09-25 | |
PCT/IB2009/000287 WO2009104074A2 (en) | 2008-02-20 | 2009-02-19 | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
EP09712440.8A EP2257307B1 (en) | 2008-02-20 | 2009-02-19 | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2257307T1 true SI2257307T1 (sl) | 2018-09-28 |
Family
ID=40888413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200931870T SI2257307T1 (sl) | 2008-02-20 | 2009-02-19 | Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic |
Country Status (20)
Country | Link |
---|---|
US (3) | US8895014B2 (sl) |
EP (2) | EP3427749A1 (sl) |
JP (2) | JP5782258B2 (sl) |
KR (1) | KR20100123730A (sl) |
CN (1) | CN101983070B (sl) |
AU (1) | AU2009215341B2 (sl) |
CA (1) | CA2716187C (sl) |
CY (1) | CY1120512T1 (sl) |
DK (1) | DK2257307T3 (sl) |
ES (1) | ES2684129T3 (sl) |
HK (1) | HK1155938A1 (sl) |
HR (1) | HRP20181259T1 (sl) |
HU (1) | HUE039413T2 (sl) |
IL (1) | IL207350A (sl) |
LT (1) | LT2257307T (sl) |
PL (1) | PL2257307T3 (sl) |
PT (1) | PT2257307T (sl) |
SG (1) | SG10201400320TA (sl) |
SI (1) | SI2257307T1 (sl) |
WO (1) | WO2009104074A2 (sl) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074687A1 (en) | 2002-03-07 | 2003-09-12 | Eidgenössische Technische Hochschule Zürich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
BRPI0508440A (pt) | 2004-03-03 | 2007-07-24 | Revance Therapeutics Inc | composições e métodos para diagnóstico tópico e transporte terapêutico |
US10105448B2 (en) | 2005-01-11 | 2018-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Combined enteropathogen recombinant construct |
KR101453963B1 (ko) | 2005-03-03 | 2014-10-22 | 레반스 테라퓨틱스, 아이엔씨. | 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법 |
US8895014B2 (en) | 2008-02-20 | 2014-11-25 | Glycovaxyn Ag | Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells |
GB0915403D0 (en) * | 2009-09-04 | 2009-10-07 | London School Hygiene & Tropical Medicine | Protein glycosylation |
ES2660227T3 (es) * | 2009-11-19 | 2018-03-21 | Glaxosmithkline Biologicals S.A. | Sistema biosintético que produce polisacáridos inmunogénicos en células procariotas |
US9221898B2 (en) | 2010-02-11 | 2015-12-29 | The Governors Of The University Of Alberta | N-linked glycan compounds |
HUE037956T2 (hu) * | 2010-05-06 | 2018-09-28 | Glaxosmithkline Biologicals Sa | Kapszuláris Gram-pozitív bakteriális biokonjugátum vakcinák |
CA2809890A1 (en) * | 2010-09-03 | 2012-03-08 | The Governors Of The University Of Alberta | Peptide containing multiple n-linked glycosylation sequons |
KR20120062457A (ko) | 2010-12-06 | 2012-06-14 | 삼성전자주식회사 | 솔더 접합 신뢰도를 높이는 반도체 패키지용 인쇄회로기판 및 이를 포함하는 반도체 패키지 |
EP2742355B1 (en) * | 2011-08-12 | 2018-12-19 | The Governors of the University of Alberta | Method of diagnosing bacterial infections using bacterial glycoproteins |
CA2847621A1 (en) | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
US9526775B2 (en) | 2012-04-27 | 2016-12-27 | Washington University | Glycoengineered outer membrane vesicles and use thereof as vaccines |
BR112015001390A2 (pt) | 2012-07-26 | 2017-09-26 | Henry M Jackson Found Advancement Military Medicine Inc | vacina de proteína de fusão multimérica e imunoterápicos |
CN104902931A (zh) * | 2012-09-10 | 2015-09-09 | 格林考瓦因有限公司 | 包含修饰的抗原的生物缀合物及其用途 |
SG11201502638YA (en) * | 2012-10-12 | 2015-05-28 | Glycovaxyn Ag | Methods of host cell modification |
EP2724730A1 (en) * | 2012-10-29 | 2014-04-30 | Institut Pasteur | Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri |
ES2713166T3 (es) | 2012-11-07 | 2019-05-20 | Glaxosmithkline Biologicals Sa | Producción de vacuna recombinante en E. coli mediante conjugación enzimática |
MX2019001795A (es) | 2013-01-17 | 2022-07-26 | X4 Pharmaceuticals Austria Gmbh | Anticuerpo específico contra e. coli mdr. |
US9931392B2 (en) | 2013-01-18 | 2018-04-03 | London School Of Hygiene And Tropical Medicine | Glycosylation method |
GB201301085D0 (en) | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
US11220676B2 (en) * | 2013-10-11 | 2022-01-11 | Glaxosmithkline Biological Sa | Methods of host cell modification |
MX2016011055A (es) * | 2014-02-24 | 2017-10-24 | Glycovaxyn Ag | Nuevo polisacarido y usos del mismo. |
CN106794237B (zh) * | 2014-04-17 | 2022-04-12 | 葛兰素史密丝克莱恩生物有限公司 | 经修饰的宿主细胞及其用途 |
JP6590916B2 (ja) * | 2014-09-24 | 2019-10-16 | ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーThe United States Of America As Represented By The Secretary Of The Navy | 毒素原性大腸菌およびジェジュニ菌の組合せの組換えコンストラクト |
AU2015342943B2 (en) | 2014-11-05 | 2018-06-28 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against Campylobacter jejuni |
US10500261B2 (en) | 2014-11-05 | 2019-12-10 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
CN105734001B (zh) | 2014-12-08 | 2020-04-07 | 中国人民解放军军事医学科学院生物工程研究所 | 一种o抗原糖链延长的甲型副伤寒沙门氏菌及其应用 |
WO2016107818A1 (en) | 2014-12-30 | 2016-07-07 | Glycovaxyn Ag | Compositions and methods for protein glycosylation |
EP3050973A1 (en) * | 2015-01-30 | 2016-08-03 | Jennewein Biotechnologie GmbH | Fermentation process for producing monosaccharides in free form from nucleotide-activated sugars |
TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
WO2017175239A1 (en) | 2016-04-05 | 2017-10-12 | Council Of Scientific & Industrial Research | A multifunctional recombinant nucleotide dependent glycosyltransferase protein and its method of glycosylation thereof |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
GB201615427D0 (en) | 2016-09-12 | 2016-10-26 | London School Of Hygeine & Tropical Medicine | Francisella glycoconjugate vaccines |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
CN106801029B (zh) * | 2017-01-22 | 2020-05-01 | 山东大学 | 一株重组大肠杆菌及其在制备抗志贺氏菌的糖疫苗中的应用 |
GB201704117D0 (en) | 2017-03-15 | 2017-04-26 | London School Hygiene & Tropical Medicine | Oligosaccharyl Transferase polypeptide |
US11179454B2 (en) | 2017-03-15 | 2021-11-23 | London School Of Hygiene And Tropical Medicine | Whole cell vaccines |
GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
WO2019175145A1 (en) | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccines against urinary tract infections |
US11530432B2 (en) * | 2018-03-19 | 2022-12-20 | Northwestern University | Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates |
GB201807303D0 (en) | 2018-05-03 | 2018-06-20 | London School Of Hygeine & Tropical Medicine | Glyconjugate vaccines |
JP2022513458A (ja) | 2018-12-12 | 2022-02-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | O-結合型グリコシル化のための修飾キャリアタンパク質 |
AU2020240075A1 (en) | 2019-03-18 | 2021-10-14 | Janssen Pharmaceuticals, Inc. | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof |
MX2021011445A (es) | 2019-03-18 | 2021-10-13 | Janssen Pharmaceuticals Inc | Bioconjugados de polisacaridos de antigenos o de e. coli, metodos de produccion y metodos de uso de los mismos. |
EP3757217A1 (en) | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Methods for protein purification |
EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
WO2021028303A1 (en) * | 2019-08-09 | 2021-02-18 | Glaxosmithkline Biologicals Sa | Mutated pglb oligosaccharyltransferase enzymes |
EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
WO2021144369A1 (en) | 2020-01-16 | 2021-07-22 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
US20230346902A1 (en) | 2020-06-18 | 2023-11-02 | Glaxosmithkline Biologicals Sa | Shigella-Tetravalent (Shigella4V) Bioconjugate |
MX2022016589A (es) | 2020-06-25 | 2023-02-01 | Glaxosmithkline Biologicals Sa | O-antigeno de klebsiella pneumoniae. |
US20220088165A1 (en) | 2020-09-17 | 2022-03-24 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
IL301880A (en) * | 2020-11-30 | 2023-06-01 | Janssen Pharmaceuticals Inc | Analytical method for glycoconjugation using a capillary-based immunoassay system |
KR20230125842A (ko) | 2021-01-12 | 2023-08-29 | 얀센 파마슈티칼즈, 인코포레이티드 | FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도 |
BR112023019874A2 (pt) | 2021-04-01 | 2023-11-07 | Janssen Pharmaceuticals Inc | Produção de bioconjugados de e. coli o18 |
CN117098550A (zh) | 2021-04-08 | 2023-11-21 | 杨森制药公司 | 生物缀合物生产方法 |
WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3584198D1 (de) | 1984-08-01 | 1991-10-31 | Boehringer Ingelheim Int | Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen. |
US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
EP0646175B1 (en) * | 1992-06-18 | 2005-12-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant pseudomonas exotoxin with increased activity |
EP0726318A1 (en) | 1993-05-14 | 1996-08-14 | The Upjohn Company | An acceptor polypeptide for an N-acetylgalactosaminyltransferase |
US6503744B1 (en) | 1999-02-01 | 2003-01-07 | National Research Council Of Canada | Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics |
CA2363297C (en) | 1999-03-02 | 2011-08-09 | Michael J. Betenbaugh | Engineering intracellular sialylation pathways |
JP2004528001A (ja) | 2000-05-12 | 2004-09-16 | ネオーズ テクノロジーズ, インコーポレイテッド | インビトロにおけるフコシル化組換えグリコペプチド |
PT1294910E (pt) | 2000-06-30 | 2009-02-16 | Vib Vzw | Modificação da glicosilação de proteínas em pichia pastoris |
KR20130101592A (ko) | 2002-03-07 | 2013-09-13 | 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 | 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계 |
WO2003074687A1 (en) | 2002-03-07 | 2003-09-12 | Eidgenössische Technische Hochschule Zürich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
CA2494223C (en) | 2002-08-01 | 2012-10-02 | National Research Council Of Canada | Campylobacter glycans and glycopeptides |
CA2534360C (en) * | 2003-08-01 | 2014-01-28 | David M. Neville | Methods for expression and purification of immunotoxins |
EP1756149B1 (en) | 2004-05-24 | 2013-09-04 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Live, oral vaccine for protection against shigella dysenteriae serotype 1 |
ATE483027T1 (de) * | 2005-05-11 | 2010-10-15 | Eth Zuerich | Rekombinante n-glykosylierte proteine aus prokaryontischen zellen |
US8895014B2 (en) * | 2008-02-20 | 2014-11-25 | Glycovaxyn Ag | Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells |
HUE037956T2 (hu) | 2010-05-06 | 2018-09-28 | Glaxosmithkline Biologicals Sa | Kapszuláris Gram-pozitív bakteriális biokonjugátum vakcinák |
-
2009
- 2009-02-19 US US12/735,773 patent/US8895014B2/en active Active
- 2009-02-19 PL PL09712440T patent/PL2257307T3/pl unknown
- 2009-02-19 DK DK09712440.8T patent/DK2257307T3/en active
- 2009-02-19 EP EP18176145.3A patent/EP3427749A1/en active Pending
- 2009-02-19 HU HUE09712440A patent/HUE039413T2/hu unknown
- 2009-02-19 ES ES09712440.8T patent/ES2684129T3/es active Active
- 2009-02-19 LT LTEP09712440.8T patent/LT2257307T/lt unknown
- 2009-02-19 CN CN200980110137.XA patent/CN101983070B/zh active Active
- 2009-02-19 PT PT09712440T patent/PT2257307T/pt unknown
- 2009-02-19 SG SG10201400320TA patent/SG10201400320TA/en unknown
- 2009-02-19 EP EP09712440.8A patent/EP2257307B1/en active Active
- 2009-02-19 JP JP2010547265A patent/JP5782258B2/ja active Active
- 2009-02-19 SI SI200931870T patent/SI2257307T1/sl unknown
- 2009-02-19 KR KR1020107020946A patent/KR20100123730A/ko not_active Application Discontinuation
- 2009-02-19 WO PCT/IB2009/000287 patent/WO2009104074A2/en active Application Filing
- 2009-02-19 CA CA2716187A patent/CA2716187C/en active Active
- 2009-02-19 AU AU2009215341A patent/AU2009215341B2/en active Active
-
2010
- 2010-08-02 IL IL207350A patent/IL207350A/en active IP Right Grant
-
2011
- 2011-08-26 HK HK11109025.7A patent/HK1155938A1/zh not_active IP Right Cessation
-
2014
- 2014-10-23 US US14/522,254 patent/US10835592B2/en active Active
-
2015
- 2015-07-17 JP JP2015142997A patent/JP6122071B2/ja active Active
-
2018
- 2018-07-31 CY CY20181100794T patent/CY1120512T1/el unknown
- 2018-08-02 HR HRP20181259TT patent/HRP20181259T1/hr unknown
-
2020
- 2020-10-02 US US17/061,687 patent/US11944675B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181259T1 (hr) | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica | |
SG10201608059VA (en) | Recombinant vwf formulations | |
SI2349314T1 (sl) | Liofilizirane rekombinantne VWF formulacije | |
HK1223946A1 (zh) | 生物活性肽 | |
IL202213A0 (en) | Recombinant protein production in avian ebxr cells | |
IL193721A0 (en) | Polypeptide producing cells | |
ZA201101166B (en) | Modified bovine g-csf polypeptides and their uses | |
HK1244426A1 (zh) | 治療性蛋白質製劑 | |
EP2403535A4 (en) | COMPATIBILIZED ELECTROLYTIC FORMULATIONS | |
GB2462761B (en) | Protein formulation | |
EP2557088A4 (en) | PHYSIOLOGICALLY ACTIVE PEPTIDES | |
ZA201104670B (en) | Pharmaceutical composition comprising aleglitazar | |
EP2102231A4 (en) | IMPROVED EXPRESSION SYSTEM FOR RECOMBINANT HUMAN ARGINASE I | |
ZA201105784B (en) | Recombinant porcine chymotrypsin | |
EP2254901A4 (en) | THERAPEUTIC PEPTIDES | |
EP2314701A4 (en) | RECOMBINANT EXPRESSION VECTOR FOR ANIMAL CELL | |
GB2462726B (en) | Protein expression | |
EP2264057A4 (en) | RECOMBINANT ANTIGEN | |
GB0803594D0 (en) | Protein formulation | |
GB0807929D0 (en) | Protein formulation | |
GB0922155D0 (en) | Interferon 8 fusion proteins | |
GB0811893D0 (en) | Protein expression | |
GB0810567D0 (en) | Protein expression |